NASDAQ:ELOX
Eloxx Pharmaceuticals Inc. Stock News
$0.80
+0.0430 (+5.68%)
At Close: May 30, 2024
Will Eloxx Continue to Surge Higher?
11:38am, Friday, 27'th Dec 2019
As of late, it has definitely been a great time to be an investor in Eloxx.
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX): What Does Its Beta Value Mean For Your Portfolio?
12:45pm, Tuesday, 24'th Dec 2019
Anyone researching Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) might want to consider the historical volatility of the...
Hedge Funds Have Never Been This Bullish On Eloxx Pharmaceuticals, Inc. (ELOX)
11:41pm, Sunday, 22'nd Dec 2019
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before last year's Q4 market crash that the stock market is overvalued due to a low interest rate environment that le
Eloxx Pharmaceuticals to Present at the Biotech Showcase™ 2020 on January 14, 2020
12:00pm, Wednesday, 18'th Dec 2019
Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal
Edited Transcript of ELOX earnings conference call or presentation 5-Nov-19 9:30pm GMT
10:09pm, Wednesday, 11'th Dec 2019
Q3 2019 Eloxx Pharmaceuticals Inc Earnings Call
Eloxx Pharmaceuticals, Inc. (ELOX) Shares March Higher, Can It Continue?
12:43pm, Friday, 06'th Dec 2019
As of late, it has definitely been a great time to be an investor in Eloxx Pharmaceuticals, Inc. (ELOX).
Eloxx Pharmaceuticals to Present at the Evercore ISI 2nd Annual HealthCONx on December 4th, 2019
12:00pm, Tuesday, 19'th Nov 2019
Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal
Eloxx Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019
12:00pm, Monday, 18'th Nov 2019
Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal
Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019
03:00pm, Thursday, 07'th Nov 2019
Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal
Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update
09:01pm, Tuesday, 05'th Nov 2019
-Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On track to report top line Phase 2 data in nephropathic cystinosis this.
Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and
NEW YORK , Oct. 23, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty
Eloxx Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on November 5, 2019
12:41pm, Thursday, 10'th Oct 2019
Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal
